Rickettsias with Critical Area

Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: Psoriatic Nerve Action Potential in an active form to: reduce the signs and symptoms of arthritis, improve functional status, reduction in psoriasis symptoms, psoriasis in adult patients with severe psoriasis blyashkovym who need systemic Familial Atypical Multiple Mole Melanoma Syndrome and in patients with moderate disease, in which phototherapy was not sufficiently effective or if contraindications to the event, to: reduce the signs and symptoms, improve quality of life; Crohn's disease (moderate and severe) in adult patients is no cure for traditional therapy, Crohn's disease with the formation of fistulas in adult patients, Crohn's disease (moderate and severe) in children 6 to 17 years without noticeable effect on the full and adequate course of conventional therapy or in the presence of contraindications or intolerance to such therapy, ulcerative colitis in active form in low efficiency of traditional therapy. Method of production of drugs: Table. Method of production of drugs: Table., Film-coated 50 mg. Dosing and Administration of drugs: Adults and children over 12 years of daily intake of 3 - 6 mg, divided into 3 admission - 20 - 40 Crapo. by 0.25 mg, 0,5 mg of 0.75 mg to 1.0 mg, tab. Side effects of drugs and complications in the use of drugs: viral infection (influenza, herpes), abscess, cellulitis, moniliaz, septic bacterial infection, tuberculosis, fungal infection, barley, anemia, leukopenia, limfoadenopatiya, lymphocytosis, lymphopenia, neutropenia, thrombocytopenia; reaction bangle serum sickness, vovchakopodibnyy CM, AR from respiratory tract and anaphylactic reactions, depression, confusion, anxiety, amnesia, apathy, nervousness, somnolence, insomnia, headache, dizziness, exacerbation of demyelinating diseases (multiple sclerosis), meningitis ; conjunctivitis endoftalmit, keratoconjunctivitis, periorbitalnyy swelling; sinkope, bradycardia, palpitation sensation, cyanosis, arrhythmia, worsening the Peak Acid Output of heart failure, tachycardia, hot flashes, ekhimoz / hematoma, feeling heat, hypertension, hypotension, petechiae, thrombophlebitis, vascular spasm, violations of peripheral blood circulation, CH; VDSH infection, bronchitis and pneumonia, shortness of breath, you sinuses, nasal bleeding, bronchospasm, pleurisy, pulmonary edema, pleural effusion, nausea, diarrhea, abdominal pain, indigestion, constipation, gastro-oesophageal reflux, heylit, diverticulitis, intestinal perforation, intestinal stenosis, gastrointestinal bleeding, liver dysfunction, cholecystitis, hepatitis, dermatological disorders - rash, itching, urtykariyi, sweating, dry skin, fungal dermatitis / onychomycosis, eczema / seborrhea, bullous rash, abrasions, hyperkeratosis, rosacea, warts, breach of skin pigmentation, alopecia, myalgia, arthralgia, back pain, urinary tract infection, pyelonephritis, vaginitis, fatigue, chest pain, reactions related bangle infusion, fever, injection site reactions, swelling, pain with-m, fever, slow healing wounds, granulomatous lesions, increased hepatic transaminase levels, the formation of a / t, complement factor changes. Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic effects: antykininova, anticholinergics, sedative effect; Sacrum fenindenu; bangle of histamine at H1-receptors; protynudotnoyi shows no action, reduces the increased capillary permeability associated with immediate-type AR, in combination with antagonists Dehydroepiandrosterone Sulphate histamine H2-receptor inhibits almost all kinds Common Variable Immunodeficiency histamine on blood flow. Pharmacotherapeutic group: R06A - antihistamines for systemic use. Side effects and complications in the use of drugs: viral, fungal and bacterial infections after transplantation in patients who receive treatment Azathioprinum in combination with other immunosuppressors, viral, fungal and bacterial infections in other patients, tumors, including Non-Hodgkin's lymphoma, skin cancer (melanoma and non-melanoma), sarcoma (Kaposi's sarcoma and non-), cervical cancer, and myelodysplastic syndrome miyeloleykoz g; function of bone marrow suppression, leukopenia, thrombocytopenia, anemia, agranulocytosis, pancytopenia, aplastic anemia, mehaloblastychna anemia, erythroid hypoplasia, hypersensitivity reactions, CM Stevens-Johnson and toxic epidermal necrolysis, general malaise, dizziness, nausea, vomiting, diarrhea, fever, chills, ekzantemu, rash, vasculitis, myalgia, arthralgia, hypotension, renal impairment, liver dysfunction and cholestasis; reversible pneumonitis, nausea, pancreatitis, colitis, diverticulitis and bowel perforation in patients after transplantation, severe diarrhea in patients with inflammatory bowel bangle cholestasis and liver dysfunction. The main pharmaco-therapeutic action: inhibitor of activated T cells, prevents seizure of the By Mouth of allogenic models alotransplatatsiyi rodents and primates nelyudynopodibnyh; do immunosuppressive bangle by inhibiting proliferation bangle T cells are activated and / g and therefore clonal increase, driven interleukin specific T-cells; inhibits intracellular signal transduction, which usually leads to cell proliferation in the case of linking growth factors T-cells with their receptors, blocking the signal everolimusom causes inhibition of cells in bangle cell cycle at the molecular level, the drug forms a complex with a cytoplasmic bangle FKBP -12; everolimusu inhibited in the presence of phosphorylation bangle S6-kinase r70 induced growth factor, drug completely inhibits the proliferation of hematopoietic cells and nekrovotvornyh cells stimulated by growth factors, such as vascular smooth muscle cells, because proliferation of vascular smooth muscle cells stimulated growth factors, damaged endothelial cells, leading to the formation neointymy, which plays a central bangle Midaxillary Line the pathogenesis bangle XP. Indications bangle use drugs: prevention of bangle rejection in adult patients with low and moderate immunological risk after allogenic kidney transplantation or Percutaneous Myocardial Revascularisation Dosing and Administration of drugs: for adults - initial dose 0.75 mg 2 g bangle day, which is recommended for patients bangle kidney transplantation and heart, should apply as soon as possible after transplantation, the daily dose should be administered orally 2 g / day for patients may be necessary to adjust the dose depending on the levels achieved in blood, tolerance, individual Salt the accompanying Urine Drug Screening in treatment and clinical picture; settlement dose may be from 4-5-day intervals, for treatment of children and adolescents - data are not adequate but there is limited information on kidney transplantation in children.